"Nelfinavir/chemistry"[MeSH] - Search Results

Year	Number of Results
1995	1
1997	1
1998	1
2000	5
2001	3
2002	4
2003	4
2004	4
2005	7
2006	6
2007	11
2008	5
2009	15
2010	4
2011	6
2012	2
2014	3
2015	5
2016	7
2017	2
2018	3
2019	2
2020	5
2021	2
2022	1
2024	0

1

Translating the anticancer properties of eEF2K.

De Gassart A, Martinon F. De Gassart A, et al. Cell Cycle. 2017 Feb 16;16(4):299-300. doi: 10.1080/15384101.2016.1254974. Epub 2016 Nov 10. Cell Cycle. 2017. PMID: 27830984 Free PMC article. No abstract available.

2

Nelfinavir: a review of its use in the management of HIV infection.

Perry CM, Frampton JE, McCormack PL, Siddiqui MA, Cvetković RS. Perry CM, et al. Drugs. 2005;65(15):2209-44. doi: 10.2165/00003495-200565150-00015. Drugs. 2005. PMID: 16225378 Review.

3

An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs.

Bhattarai D, Singh S, Jang Y, Hyeon Han S, Lee K, Choi Y. Bhattarai D, et al. Curr Top Med Chem. 2016;16(19):2156-68. doi: 10.2174/1568026616666160216153618. Curr Top Med Chem. 2016. PMID: 26881715 Review.

4

In-utero exposure to nelfinavir-ethyl methyl sulfone.

Hleyhel M, Goujon S, Sibiude J, Blanche S, Warszawski J; on behalf the ANRS French Perinatal Cohort study Group. Hleyhel M, et al. AIDS. 2016 Nov 13;30(17):2729-2730. doi: 10.1097/QAD.0000000000001254. AIDS. 2016. PMID: 27662548

5

Nelfinavir and Its Active Metabolite M8 Are Partial Agonists and Competitive Antagonists of the Human Pregnane X Receptor.

Burk O, Kronenberger T, Keminer O, Lee SML, Schiergens TS, Schwab M, Windshügel B. Burk O, et al. Mol Pharmacol. 2021 Mar;99(3):184-196. doi: 10.1124/molpharm.120.000116. Epub 2021 Jan 22. Mol Pharmacol. 2021. PMID: 33483427

6

Nelfinavir and nelfinavir analogs block site-2 protease cleavage to inhibit castration-resistant prostate cancer.

Guan M, Su L, Yuan YC, Li H, Chow WA. Guan M, et al. Sci Rep. 2015 Apr 16;5:9698. doi: 10.1038/srep09698. Sci Rep. 2015. PMID: 25880275 Free PMC article.

7

A review of nelfinavir for the treatment of HIV infection.

Olmo M, Podzamczer D. Olmo M, et al. Expert Opin Drug Metab Toxicol. 2006 Apr;2(2):285-300. doi: 10.1517/17425255.2.2.285. Expert Opin Drug Metab Toxicol. 2006. PMID: 16866614 Review.

8

The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?

Lutz WK. Lutz WK. Toxicol Lett. 2009 Nov 12;190(3):239-42. doi: 10.1016/j.toxlet.2009.07.032. Epub 2009 Aug 18. Toxicol Lett. 2009. PMID: 19695319

9

Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.

Gocke E, Bürgin H, Müller L, Pfister T. Gocke E, et al. Toxicol Lett. 2009 Nov 12;190(3):254-65. doi: 10.1016/j.toxlet.2009.03.016. Epub 2009 Mar 28. Toxicol Lett. 2009. PMID: 19857796 Review.

10

Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.

Hirt D, Mentré F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Tréluyer JM; COPHAR2- ANRS Study Group. Hirt D, et al. Br J Clin Pharmacol. 2008 Apr;65(4):548-57. doi: 10.1111/j.1365-2125.2007.03039.x. Epub 2007 Oct 8. Br J Clin Pharmacol. 2008. PMID: 17922881 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

100 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Results by year